• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1308543 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type' C! S8 j& M6 m0 [+ k/ x- W6 J
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 # Q, z; U) a7 }
+ Author Affiliations
9 r0 i# Q% |, D; d5 @9 B; r
, h$ ]/ ]0 @* v, Q5 j7 a; }2 ]$ V1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan + _/ F. @+ n5 |) M+ n
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
$ I3 d, I+ X9 b8 O3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 Y0 |% L1 ]  c: w4 P4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan / X  j; Y& V) w& ?
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
8 {# @* k. E* l' o4 l/ N& o6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : \; P5 S4 M  ]  w! A7 j4 l( ~
7Kinki University School of Medicine, Osaka 589-8511, Japan ) Q% p. g& v( e: i& B) P( S
8Izumi Municipal Hospital, Osaka 594-0071, Japan - [% a) D7 e  f/ p( W' E9 m
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
" {4 E. O3 k+ o+ wCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 4 f# q: Y) t& J' E8 m, f
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
( y2 E! P! `1 Z9 U$ _7 x  \1 K  B) H" O# c, }
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type + B3 G7 F' B. ^$ U6 @- O
% r3 z- Y2 o4 M
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
, ?# N. a' H3 b5 W9 i0 x( B6 I3 T" \8 P& S9 ]
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  9 m, m& |, n) |/ ], t5 Q' f- o

& f' w2 p, L. s; q" c1 T' JPublished online on: Thursday, December 1, 2011
. e5 O9 E/ b( ~
1 _$ P9 J) }' F' o. @Doi: 10.3892/ol.2011.507
2 M; R( Q9 N  w% \5 u
3 o5 S5 @$ f8 NPages: 405-410 6 D* [0 k' @- t1 W/ C5 |
+ t) V9 S* y" Q" Z
Abstract:
0 g0 K3 a: v! hS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.2 C: ~) X( c* S5 O6 m  W9 a
1 J+ x6 o5 w# @9 [% i& [$ z
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
: W$ B$ ~( g; w5 Y! |  R# uF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 . {+ ^. M- x  O! y
+ Author Affiliations
) V9 o% E9 B3 G3 @; c; V1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
9 r/ }. ?; `- t4 M2Department of Thoracic Surgery, Kyoto University, Kyoto
) Y9 {9 z" g' U, l  |3 i# Z3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan 6 O+ `" B0 D  i; `- j
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp 9 h9 @8 K  Z) ^$ w6 k/ p4 K( q& {
Received September 3, 2010.
% p+ t  S9 D5 pRevision received November 11, 2010.
! Q1 j  _1 x9 l! I1 qAccepted November 17, 2010.
5 e5 ?3 ~/ ]% D1 n1 hAbstract. B# A& N% I! h( `# L# U
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
5 ]- @, Q+ y1 _. C  e# mPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. * z( G7 z) D4 B; a) r! Q$ l
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
- Q; y& h/ R( x$ B5 f& I% l- M% G' \: r( zConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. % L! ^5 ?  J& {) `, M1 S
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
9 Y3 y. ]9 k/ i3 v( I今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?" G( y! C7 Z5 c! O6 ]
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
/ \- f( |8 r2 p+ Phttp://clinicaltrials.gov/ct2/show/NCT01523587$ t5 s# D" V3 s  c% W2 Y
0 T& h1 Y) K+ J' U+ }$ l
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC. ]! I' ^' j; s: W" q
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 , X# V9 k. S- y0 A; Q5 F4 \" k
! S8 T/ U  t' G7 S7 d9 K# X
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
+ T' r4 p6 u9 u0 c* \至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
0 d3 b+ n! D0 g+ S; @2 A) M) Y" ?从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。1 p" [- f+ _1 q# a
至今为止,未出 ...
' O+ h6 z9 r# s1 I
没有副作用是第一追求,效果显著是第二追求。8 B6 |8 o$ O. H' K
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表